Helicobacter and sulforaphane: new developments in research (2024–2025)

Antibacterial action vs. mucosal cytoprotection: how research understands it today

H. pylori is a “silent roommate” of the stomach, which in some people causes no symptoms, but in others triggers chronic gastritis, peptic ulcer disease and increases the risk of stomach cancer. In clinical practice, therefore, a simple rule applies: if the infection is confirmed and treatment is indicated, eradication antibiotic therapy remains the standard according to the recommendations of gastroenterology societies. (med.emory.edu)

Sulforaphane (SFN) – a bioactive molecule from broccoli sprouts – has become relevant to this topic because it has a dual effect profile:

1. direct antibacterial/anti-virulence effect on H. pylori (laboratory and animal data),
2. support for mucosal cytoprotection via antioxidant and anti-inflammatory response pathways (especially Nrf2). (Frontiers)

It is important to say this openly: SFN appears in human studies to be more of a “modulator of stress and inflammation” than a standalone eradication treatment. However, this does not mean that it is worthless – quite the contrary: in 2024–2025, syntheses and mechanistic studies were added that better explain where exactly it can make sense and what still needs to be clinically confirmed. (Frontiers)

1) Why is SFN interested in H. pylori research?

A) Direct action against bacteria (not just “immunity”)

Older but still fundamental studies have shown that SFN can act against H. pylori even in strains resistant to certain antibiotics (in vitro) and reduce colonisation in infection models. (ResearchGate)

Modern reviews (2024) summarised this pragmatically: Brassicaceae (broccoli/sprouts) and their isothiocyanates have both antimicrobial and “anti-virulence” profiles (e.g., effects on colonisation, inflammatory context, mucosal stress responses), but clinical evidence is currently heterogeneous in terms of doses, forms, and endpoints. (Frontiers)

B) Mucosal protection: Nrf2, oxidative stress, and low-grade inflammation

SFN is a known activator of the Nrf2 pathway – i.e. the “internal” cell defence system (antioxidant enzymes, phase II detoxification enzymes). In the case of H. pylori, this is not just a cosmetic issue: the infection is associated with oxidative stress and chronic low-level inflammation of the mucosa. It is here that SFN can be understood as a molecule that can reduce the biological cost of infection (inflammation, mucosal damage), even if it cannot “erase” it on its own. (Frontiers)

2) What do clinical data in humans show (and where are the limitations)?

The most cited human intervention with broccoli sprouts (placebo control with alfalfa) showed that daily consumption of sprouts for 8 weeks resulted in a decrease in colonisation markers (urease breath test, stool antigen) and a simultaneous decrease in gastric inflammation markers (pepsinogens). However, the effect did not typically result in universal eradication in all individuals. (aacrjournals.org)

Further clinical work with broccoli sprout extracts (BSES) supports the image of an “antioxidant + anti-inflammatory” effect with changes in some parameters, but again – not as a substitute for standard eradication. (PMC)

And this is where the progress of 2024–2025 comes in: new reviews and mechanistic studies indicate that the greatest clinical opportunity for SFN is likely as an adjuvant (supplement to a regimen/therapy) – in the sense of supporting mucosal resistance, reducing inflammatory burden, and possibly reducing bacterial “activity/virulence”. (Frontiers)

3) What specifically was added in 2024–2025?

2024: Better mapping of evidence (and a sober framework)

More systematic reviews of brassicaceae/isothiocyanates in H. pylori in 2024 summarise that:

• there is biological plausibility (antimicrobial + cytoprotective mechanisms),
• However, clinical studies vary (form: sprouts vs extract; dosage; duration; endpoints).
• Therefore, it is fair to talk about SFN as a potentially useful support, not as a "standalone eradication". (Frontiers)

2025: mechanisms in greater depth (metabolomics, damage pathways)

In 2025, studies were published on animal models that delve deeper into the metabolic changes associated with H. pylori and how SFN can “correct” some of them (metabolomic profiles, inflammatory and stress pathways). This is important: it moves the field from “SFN is an antioxidant” to more specific biological mechanisms. (ResearchGate)

At the same time, newer forms of presentations (conference outputs) on the link between Nrf2/SFN and the inflammatory response of the stomach in H. pylori are also appearing in the professional community – the trend is clear: SFN is being investigated as a modulator of the host response + anti-virulence factor. (PMC)

4) Practical takeaways (no marketing, no illusions)

1. Diagnosis is key. If there are symptoms or risk factors, this includes a breath urease test, stool antigen test, or endoscopy as indicated – and treatment is guided by recommendations. (med.emory.edu)
2. SFN makes the most biological sense as an adjunct to treatment/adjuvant, not as a substitute for eradication. Clinical data show a reduction in markers of colonisation and gastric inflammation rather than universal eradication. (genscript.com)
3. If SFN is used (either from the key or the add-on), the key variables are:
   • form (glucoraphanin + myrosinase vs. "ready-made" SFN),
   • real bioactivation (myrosinase, gut microbiota, processing),
   • dose and duration,
   • measurable endpoints (UBT, stool antigen, pepsinogens, symptoms). (Frontiers)
4. Safety and context: SFN from food is generally considered safe; for supplements and long-term use, individual assessment is advisable (especially for medicines, gastrointestinal problems or specific diagnoses). This is not a substitute for medical advice.

Sources and scientific references (2024–2025 + key clinical studies)

2024 – prehľad Brassicaceae/izotiokyanáty a H. pylori:
Frontiers in Medicine (systematickejší prehľad): https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1343179/full

2025 – mechanistická štúdia (metabolomika, H. pylori model + sulforafán):
International Journal of Molecular Sciences (2025): https://www.mdpi.com/1422-0067/26/10/4903

Kľúčová humánna RCT s brokolicovými klíčkami (marker kolonizácie + gastritída):
Cancer Prevention Research (2009) abstract: https://aacrjournals.org/cancerpreventionresearch/article-abstract/2/4/353/47768
(stručná sumarizácia výsledkov): https://www.genscript.com/reference_peer-reviewed_literature_542.html?journal=Cancer+Prev+Res+%28Phila%29.&pubmed_id=19349290

Klinická práca s extraktom brokolicových klíčkov (BSES) – H. pylori hustota + oxidácia:
PMC fulltext (Chang 2014/2015): https://pmc.ncbi.nlm.nih.gov/articles/PMC4477992/
Gut and Liver stránka: https://www.gutnliver.org/journal/view.html?doi=10.5009/gnl14040

2024 – Yanaka a kol. (PDF; spomína predošlé H. pylori dáta a SFN/Nrf2 rámec):
https://www.ffhdj.com/index.php/ffhd/article/download/1440/4044/10228

Odporúčania k liečbe H. pylori (ACG guideline – PDF):
https://socgastro.org.br/novo/wp-content/uploads/2024/12/ACG-Clinical-Guideline-Treatment-of-Helicobacter-pylori-Infection.pdf
(prehľad/hightlights): https://gi.org/journals-publications/ebgi/schoenfeld_sep2024/